[High blood pressure and associated lifestyles in an urban population in Argentina].

Introduction: The American Heart Association (AHA/ACC) sets as a goal for blood pressure (BP) control not to exceed values of 130/80 mmHg, both in individuals with and without a diagnosis of hypertension (HT), standards not evaluated so far in the Argentine population. The objective was to determine the prevalence of high BP (HBP) in individuals with and without a diagnosis of HT taking into account the AHA/ACC criteria and to evaluate its association with sociodemographic and lifestyle factors.

Materials And Methods: Cross-sectional populationbased study in 911 persons >18 years of age in Córdoba, Argentina (period 2020-2022).

Social Determinants of Breast Cancer Screening: A Multilevel Analysis of Proximal and Distal Factors Related to the Practice of Mammography.

Background: Mammography is crucial for early breast cancer detection. In Latin America, Argentina faces a significant breast cancer burden, with varying mammography rates. The social factors influencing mammography practices remain unclear.

A fluorescence-based assay for measuring polyamine biosynthesis aminopropyl transferase-mediated catalysis.

Polyamines are polycationic molecules that are crucial in a wide array of cellular functions. Their biosynthesis is mediated by aminopropyl transferases (APTs), which are promising targets for antimicrobial, antineoplastic, and antineurodegenerative therapies. A major limitation in studying APT enzymes, however, is the lack of high-throughput assays to measure their activity.

Exploring the quality of urban green spaces and their association with health: An epidemiological study on obesity using Street View technology.

Objectives: Evidence suggests that access to urban green spaces (UGS) may encourage physical exercise and impact nutritional status and health. Nevertheless, the quality of UGS is an understudied area. Novel digital tools allow the analysis of urban environments.

3-Position Biaryl Endochin-like Quinolones with Enhanced Antimalarial Performance.

ELQ-300 is a potent antimalarial drug with activity against blood, liver, and vector stages of the disease. A prodrug, , exhibits reduced crystallinity and improved in vivo efficacy in preclinical testing, and currently, it is in the developmental pipeline for once-a-week dosing for oral prophylaxis against malaria. Because of the high cost of developing a new drug for human use and the high risk of drug failure, it is prudent to have a back-up plan in place.